OncoSil Medical Limited (ASX:OSL)

Australia flag Australia · Delayed Price · Currency is AUD
0.625
-0.005 (-0.79%)
Mar 6, 2026, 3:25 PM AEST
-73.96%
Market Cap 14.76M
Revenue (ttm) 3.72M
Net Income (ttm) -12.92M
Shares Out 23.62M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,585
Average Volume 51,817
Open 0.630
Previous Close 0.630
Day's Range 0.625 - 0.645
52-Week Range 0.620 - 2.400
Beta 1.16
RSI 30.25
Earnings Date Mar 3, 2026

About OncoSil Medical

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2005
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol OSL
Full Company Profile

Financial Performance

In fiscal year 2025, OncoSil Medical's revenue was 1.54 million, a decrease of -1.92% compared to the previous year's 1.57 million. Losses were -15.10 million, 26.7% more than in 2024.

Financial Statements

News

There is no news available yet.